Will have accountability for delivering new products
Scotsman Martin Mackay is to leave Pfizer to take up the newly created position of president of r&d at AstraZeneca. He will have overall accountability for delivering new products – small molecules and biologics – from the Anglo-Swedish pharmaceutical company’s pipeline. He will start his new role on 1 July and will be based at the company’s headquarters in London, UK.
Mackay currently heads up Pfizer’s PharmaTherapeutics Research & Development division and is a member of the Pfizer Executive Leadership Team.
Martin Mackay will head r&d at AstraZeneca
Prior to joining Pfizer in 1995, Mackay held several discovery and development roles culminating with his appointment as head of Molecular and Cell Biology, CNS Research at Ciba-Geigy.
Mackay has a first class honours degree in Microbiology from Heriot-Watt University and a PhD in Molecular Genetics from the University of Edinburgh.
‘Martin has impeccable scientific and leadership credentials combined with extensive experience of the pharmaceutical industry. I am delighted he is joining us,’ said David Brennan, chief executive of AstraZeneca. ‘We have a clear and unambiguous commitment to creating value through innovative biopharmaceuticals with research and development at the heart of our strategy.’
Mackay will report to Brennan and will be a member of AstraZeneca’s Senior Executive Team.